Actively Recruiting
Treat-to-Target and Disease Modification in Inflammatory Bowel Disease: A Worldwide Routine Practice Study
Led by AbbVie · Updated on 2026-03-27
2000
Participants Needed
4
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, is a chronic condition causing inflammation in the digestive tract. This observational study is designed to evaluate how a treat-to-target (T2T) strategy is being applied worldwide in real-life settings for adults with IBD, and how this approach relates to disease outcomes over a 24-month period. The study collects data retrospectively and focuses on IBD as a whole, as well as separately for Crohn's Disease and Ulcerative Colitis. Participants in this study will not receive any new treatments as part of the trial but will continue their usual care as managed by their healthcare providers. The study involves reviewing medical records from the past 24 months using electronic case report forms to gather relevant information about treatment approaches and disease progression. No additional visits or interventions are required from the participants. During the study, researchers will analyze the percentage of participants managed using the T2T strategy within 12 weeks and examine how this relates to disease outcomes. Since this is a retrospective chart review, there are no extra procedures or visits, and no additional burden for participants. The study will follow participants' existing medical records for a total of 24 months from the inclusion date.
CONDITIONS
Brief Title
A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult male and female participants (≥ 18 years old) at the inclusion date who present within the usual course of care
- Participants able to provide voluntary informed consent prior to any study data collection
- Participant diagnosed with Crohn's Disease or Ulcerative Colitis for at least 24 months at the inclusion date
- With ≥ 24 months of available medical records from the inclusion date
You will not qualify if you...
- Participants who had received treatment with any investigational drug, device, or intervention over the past 24 months prior to enrollment
- Participants under legal protection
- History of proctocolectomy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At least 24 months
Participants who undergo routine care are observed to evaluate treat-to-target and disease modification in inflammatory bowel disease.
Follow-up visits according to standard clinical practice
Trial Site Locations
Total: 4 locations
1
Chongqing General Hospital /ID# 282777
Chongqing, Chongqing Municipality, China, 400013
Actively Recruiting
2
Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau /ID# 282775
Nîmes, Gard, France, 30029
Not Yet Recruiting
3
Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois /ID# 280265
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France, 54511
Not Yet Recruiting
4
CHU Amiens-Picardie Site Sud /ID# 280263
Amiens, Somme, France, 80054
Not Yet Recruiting
Research Team
C
Colla Cunneen
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here